Clinical trial · Observational
Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27
A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tumor and blood samples from postmenopausal women with primary breast cancer enrolled on clinical trial CAN-NCIC-MA27.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| polymorphism analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single group
- description
- DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
- interventionNames
- Genetic: polymorphism analysis
- Other: laboratory biomarker analysis
Primary outcomes (1)
- measure
- Genetic variation associated with musculoskeletal adverse events
- timeFrame
- Up to 2 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 45 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed invasive breast cancer * Complete resection of primary tumor * Stage I-III (T1-3, N0-3, M0) disease * Enrolled in clinical trial CAN-NCIC-MA27. * No locally recurrent or metastatic breast cancer * Hormone receptor status: * Estrogen receptor- or progesterone receptor-positive disease PATIENT CHARACTERISTICS: * Postmenopausal status, defined as one of the following: * At least 60 years old * Age 45-59 years with spontaneous cessation of menses for \> 12 months prior to chemotherapy or study randomization * Age 45-59 years with cessation of menses for \< 12 months or secondary to hysterectomy AND a follicle-stimulating hormone (FSH) level in the postmenopausal range (or \> 34.4 IU/L) * Age 45-59 years on hormone replacement therapy (HRT) and discontinued HRT at diagnosis of breast cancer AND FSH level in the postmenopausal range (or \> 34.4 IU/L) * Bilateral oophorectomy PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available